The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage

Bibliography

• HEDNER U, KISIEL W: Use of human Factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J. Clin. Invest. (1983) 71(6):1836-1841.
   PubMed Web of Science ®Google Scholar
• HEDNER U, BJOERN S, BERNVIL SS, TENGBORN L, STIGENDAHL L: Clinical experience with human plasma-derived Factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis (1989) 19(6):335-343.
   PubMedGoogle Scholar
• JURLANDER B, THIM L, KLAUSEN NK et al.: Recombinant activated Factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin. Thromb. Hemost. (2001) 27(4):373-384.
   PubMed Web of Science ®Google Scholar
• HOFFMAN M, MONROE DM: A cell-based model of haemostasis. Thromb. Haemost. (2001) 85:958-965.
   PubMed Web of Science ®Google Scholar
• HOFFMAN M: A cell-based model of coagulation and the role of Factor VIIa. Blood Rev. (2003) 17(1):S1-S5.
   PubMed Web of Science ®Google Scholar
• HOFFMAN M, MONROE DM, ROBERTS HR: Activated Factor VII activates Factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated Factor VII. Blood Coagul. Fibrinolysis (1998) 9(1):S61-S65.
   PubMed Web of Science ®Google Scholar
• MONROE DM, HOFFMAN M, OLIVER JA et al.: Platelet activity of high-dose Factor VIIa is independent of tissue factor. Br. J. Haematol. (1997) 99:542-547.
   PubMed Web of Science ®Google Scholar
• MONROE DM, HOFFMAN M, OLIVER JA et al.: A possible mechanism of action of activated Factor VII independent of tissue factor. Blood Coagul. Fibrinolysis (1998) 9(1):S15-S20.
   PubMed Web of Science ®Google Scholar
• ERHARDTSEN E: Pharmacokinetics of recombinant activated Factor VII. Semin Thromb. Haemost. (2000) 26:385-391.
   PubMed Web of Science ®Google Scholar
• FRIDBERG, MJ, HEDNER U, ROBERTS HR, ERHARDSTEN E: A study of the pharmacokinetics and safety of recombinant activated Factor VII in healthy Caucasian and Japanese subjects. Blood Coagul. Fibrinolysis (2005) 16(4):259-266.
   PubMed Web of Science ®Google Scholar
• HEDNER U, KRISTENSEN H, BERNTORP E et al.: Pharmacokinetics of rFVIIa in children. Haemophilia (1998) 4:355 (Abstract).
   Google Scholar
• VILLAR A, ARONIS S, MORFINI M et al.: Pharmacokinetics of activated recombinant coagulation Factor VII (NovoSeven) in children versus adults with haemophilia A. Haemophilia (2004) 10(4):352-359.
   PubMed Web of Science ®Google Scholar
• ROBERTS HR: Recombinant Factor VIIa: how safe is the stuff? Can. J. Anesth. (2005) 52(1):8-11.
   PubMed Web of Science ®Google Scholar
• ABSHIRE T, KENET G: Recombinant Factor VIIa: a review of efficacy, dosing regimens and safety in patients with congenital and acquired Factor VII or IX inhibitors. J. Thromb. Haemost. (2004) 2:899-909.
   PubMed Web of Science ®Google Scholar
• LEVI M, PETERS M, BULLER HR: Efficacy and safety of recombinant Factor VIIa for treatment of severe bleeding: a systematic review. Crit. Care Med. (2005) 33:883-890.
   PubMed Web of Science ®Google Scholar
• PARAMESWARAN R, SHAPIRO AD, GILL JC et al.: Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia (2005) 11:100-106.
   PubMed Web of Science ®Google Scholar
• MAYER SA, BRUN NC, BEGTRUP K et al.: Recombinant activated Factor VII for acute intracerebral hemorrhage. N. Engl. J. Med. (2005) 352:777-785.
   PubMed Web of Science ®Google Scholar
• MAYER SA, BRUN NC, BRODERICK J et al.: Safety and feasibility of recombinant Factor VIIa for acute intracerebral hemorrhage. Stroke (2005) 36:74-79.
   PubMed Web of Science ®Google Scholar
• MAYER SA, BRUN N, BRODERICK J et al.: Safety and preliminary efficacy of recombinant coagulation Factor VIIa in acute intracerebral hemorrhage: US Phase IIA Study. Stroke (2004) 35:332.
   Google Scholar
• MAYER SA, BRUN NC: N. Engl. J. Med. (2005) 352(20):2133-2134; author reply 2134.
   Google Scholar
• MARTINOWITZ U, MICHAELSON M: The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated Factor VIIa in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J. Thromb. Haemost. (2005) 3:640-648.
   PubMed Web of Science ®Google Scholar
• KEY NS, ALEDORT LM, BEARDSLEY D et al.: Home treatment of mild to moderate bleeding episodes using recombinant Factor VIIa (NovoSeven®) in haemophiliacs with inhibitors. Thromb. Haemost. (1998) 80:912-918.
   PubMed Web of Science ®Google Scholar
• SHAPIRO AD, GILCHRIST GS, HOOTS WK, COOPER HA, GASTINEAU DA: Prospective, randomised trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery. Thromb. Haemost. (1998) 80:773-778.
   PubMed Web of Science ®Google Scholar
• LUSHER JM, ROBERTS HR, DAVIGNON G et al.: A randomized, double-blind comparison of two dosage levels of recombinant Factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia (1998) 4:790-798.
   PubMed Web of Science ®Google Scholar
• INGERSLEV J, FREIDMAN D, GASTINEAU D et al.: Major surgery in haemophilic patients with inhibitors using recombinant Factor VIIa. Haemostasis (1996) 26(1):118-123.
   PubMedGoogle Scholar
• MCPHERSON J, TEAGUE L, LLOYD J et al.: Experience with recombinant Factor VIIa in Australia and New Zealand. Haemostasis (1996) 26(1):109-117.
   PubMedGoogle Scholar
• ARKIN S, COOPER HA, HUTTER JJ et al.: Activated recombinant human coagulation Factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the NovoSeven® emergency-use program. Haemostasis (1998) 28:93-98.
   PubMedGoogle Scholar
• LIEBMAN HA, CHEDIAK J, FINK KI, GALVEZ AG, SHAH PC, SHAH RL: Activated recombinant human coagulation Factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to Factor VIII. Am. J. Hematol. (2000) 63:109-113.
   PubMed Web of Science ®Google Scholar
• SCHARRER I: Recombinant Factor VIIa for patients with inhibitors to Factor VIII or IX or Factor VII deficiency. Haemophilia (1999) 5:253-259.
   PubMed Web of Science ®Google Scholar
• MARIANI G, TESTA MG, DI PAOLANTONIO T et al.: Use of recombinant, activated Factor Vii in the treatment of congenital Factor VII deficiencies. Vox Sang. (1999) 77:131-136.
   PubMed Web of Science ®Google Scholar
• INGERSLEV J, KNUDSEN L, HVID I, TANGE MR, FREDBERG U, SNEPPEN O: Use of recombinant Factor VIIa in surgery in factor-VII-deficient patients. Haemophilia (1997) 3:215-218.
   PubMed Web of Science ®Google Scholar
• POON MC, DEMERS C, JOBIN F et al.: Recombinant Factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood (1999) 94:3951-3953.
   PubMed Web of Science ®Google Scholar
• TENGBORN L, PETRUSON B: A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant Factor VIIa. Thromb. Haemost. (1996) 75:981-982.
   PubMed Web of Science ®Google Scholar
• POON MC, KATSAROU O, HUTH-KUEHNE A: Recombinant Factor VIIa in congenital platelet bleeding disorders. Blood (2000) 96:256a.
   Google Scholar
• D’OIRON R, MENART C, TRZECIAK MC et al.: Use of recombinant Factor VIIa in 3 patients with inherited Type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb. Haemost. (2000) 83:644-647.
   PubMed Web of Science ®Google Scholar
• JANSON TL, STORMORKEN H, PRYDZ H: Species specificity of tissue thromboplastin. Hemostasis (1984) 14:440-444.
   PubMedGoogle Scholar
• KASE F: The effect of homo- and heterologous thromboplastins on plasmas of man, seven mammalian and two avian species: a comparative study. Comp. Biochem. Physiol. (1978) 61A:65-68.
   Google Scholar
• MARTINOWITZ U, HOLCOMB JB, PUSATERI AE et al.: Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J. Trauma (2001) 50:721-729.
   PubMed Web of Science ®Google Scholar
• JEROUKHIMOV I, JEWELEWICZ D, ZAIAS J et al.: Early injection of high-dose recombinant Factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J. Trauma (2002) 53(6):1053-1057.
   PubMed Web of Science ®Google Scholar
• MOORE EE, COGBILL TH, JURKOVICH GJ et al.: Organ injury scaling: spleen and liver (1994 revision). J. Trauma (1995) 38:323-324.
   PubMed Web of Science ®Google Scholar
• SCHREIBER MA, HOLCOMB JB, HEDNER U, BRUNDAGE SI, MACAITIS JM, HOOTS K: The effect of recombinant Factor VIIa on coagulopathic pigs with grade V liver injuries. J. Trauma (2002) 53:252-259.
   PubMed Web of Science ®Google Scholar
• SCHREIBER MA, HOLCOMB JB, HEDNER U et al.: The effect of recombinant factor VIIa on noncoagulopathic pigs with Grade V liver injuries. J. Am. Coll. Surg. (2003) 196:691-697.
   PubMed Web of Science ®Google Scholar
• ODEYEMI IA, GUEST JF: Modelling the economic impact of recombinant activated Factor VII and activated prothrombin concentrate in adults with inhibitors to clotting factors VIII and IX at a comprehensive care centre in the UK. J. Med. Econ. (2002) 5:51-64.
   Google Scholar
• ODEYEMI IA, GUEST JF: Modelling the economic impact of recombinant activated Factor VII compared to activated prothrombin concentrate in the home treatment of adults with inhibitors to clotting factors VIII and IX in the UK. J. Med. Econ. (2002) 5:119-133.
   Google Scholar
• KNIGHT C, PAISLEY S, WIGHT J, JONES ML: Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia (2003) 9(4):521-540.
   PubMed Web of Science ®Google Scholar
• HENDRIKS H, MEIJER K, DE WOOLF J et al.: Reduced transfusion requirements by recombinant Factor VIIa in orthotopic liver transplantation. A pilot study. Transplantation (2001) 71:402-405.
   PubMed Web of Science ®Google Scholar
• PLANINSIC RM, VAN DER MEER J, TESTA G et al.: Safety and efficacy of a single bolus administration of recombinant Factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl. (2005) 11:895-900.
   PubMed Web of Science ®Google Scholar
• LODGE JP, JONAS S, JONES RM et al.: Efficacy and safety of repeated perioperative doses of recombinant Factor VIIa in liver transplantation. Liver Transpl. (2005) 11:973-979.
   PubMed Web of Science ®Google Scholar
• PEDEN M, MCGEE K, SHARMA G: The Injury Chart Book: A Graphical Overview Of The Global Burden Of Injuries. Geneva: World Health Organization (2002).
   Google Scholar
• CARRICO CJ, HOLCOMB JB, CHAUDRY IH: PULSE Trauma Work Group. Post Resuscitative and Initial Utility of Life Saving Efforts. Scientific priorities and strategic planning for resuscitation research and life saving therapy following traumatic injury: report of the PULSE Trauma Work Group. Acad. Emerg. Med. (2002) 9:621-626.
   PubMed Web of Science ®Google Scholar
• MOCK C, QUANSAH R, KRISHNAN R, ARRELOLA-RISA C, RIVARA F et al.: Strengthening the prevention and care of injuries worldwide. Lancet (2004) 363(9427):2172-2179.
   PubMed Web of Science ®Google Scholar
• MURRAY CJ, LOPEZ AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 349:1269-1276.
   PubMed Web of Science ®Google Scholar
• WHO: World Health Report: 2003: shaping the future. (2003).
   Google Scholar
• SAUAIA A, MOORE FA, MOORE EE et al.: Epidemiology of trauma deaths: a reassessment. J. Trauma (1995) 38:185-193.
   PubMed Web of Science ®Google Scholar
• MACKENZIE EJ, SIEGEL JH, SHAPIRO S, MOODY M, SMITH RT: Functional recovery and medical costs of trauma: an analysis by type and severity of injury. J. Trauma (1988) 28:281-297.
   PubMed Web of Science ®Google Scholar
• HOLBROOK TL, ANDERSON JP, SIEBER W, BROWNER D, HOYT DB: Outcome after major trauma: 12-month and 18-month follow-up results from the Trauma Recovery Project. J. Trauma (1999) 46:765-771.
   PubMed Web of Science ®Google Scholar
• GROUNDS M: Recombinant Factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev. (2003) 17:S11-S21.
   PubMed Web of Science ®Google Scholar
• SPIVEY M, PARR MJ: Therapeutic approaches in trauma-induced coagulopathy. Minerva Anestesiol. (2005) 71(6):281-289.
   PubMedGoogle Scholar
• MACLEOD JB, LYNN M, MCKENNEY MG et al.: Early coagulopathy predicts mortality in trauma. J. Trauma (2003) 55:39-44.
   PubMed Web of Science ®Google Scholar
• LYNN M, JEROUKHIMOV I, KLEIN Y, MARTINOWITZ U: Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med. (2002) 28(2):S241-S247.
   PubMed Web of Science ®Google Scholar
• DUTTON RP, MCCUNN M, HYDER M et al.: Factor VIIa for correction of traumatic coagulopathy. J. Trauma (2004) 57:709-719.
   PubMed Web of Science ®Google Scholar
• SHANDER A: Emerging risks and outcomes of blood transfusion in surgery. Semin. Hematol. (2004) 41(1):117-124.
   PubMed Web of Science ®Google Scholar
• COMO JJ, DUTTON RP, SCALEA TM et al.: Blood transfusion rates in the care of acute trauma. Transfusion (2004) 44(6):809-813.
   PubMed Web of Science ®Google Scholar
• MALONE DL, DUNNE J, TRACY JK et al.: Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J. Trauma (2003) 54:898-905.
   PubMed Web of Science ®Google Scholar
• VASLEF SN, KNUDSEN NW, NELIGAN PJ, SEBASTIAN HW: Massive transfusion exceeding 50 units of blood products in trauma patients. J. Trauma (2002) 53(2):291-295.
   PubMed Web of Science ®Google Scholar
• TREGGIARI MM, HUDSON LD, MARTIN DP, WEISS NS, CALDWELL E, RUBENFELD G: Effect of acute lung injury and acute respiratory distress syndrome on outcome in critically ill trauma patients. Crit. Care Med. (2004) 32:327-331.
   PubMed Web of Science ®Google Scholar
• MOORE FA, SAUAIA A, MOORE EE et al.: Postinjury multiple organ failure: a bimodal phenomenon. J. Trauma (1996) 40:501-510.
   PubMed Web of Science ®Google Scholar
• ROTONDO MF, ZONIES DH: The damage control sequence and underlying logic. Surg. Clin. North Am. (1997) 77:761-777.
   PubMed Web of Science ®Google Scholar
• SHAFI S, KAUDER DR: Fluid resuscitation and blood replacement in patients with polytrauma. Clin. Orthop. Relat. Res. (2004) 422:37-42.
   PubMedGoogle Scholar
• COATS T, ROBERTS I, SHAKUR H: Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst. Rev. (2004) 4:CD004896.pub2. DOI: 10.1002/14651858.CD004896.pub2.
   PubMedGoogle Scholar
• KENET G, WALDEN R, ELDAD A et al.: Treatment of traumatic bleeding with recombinant Factor VIIa. Lancet (1999) 354:1879.
   PubMed Web of Science ®Google Scholar
• STEIN DM, DUTTON RP: Uses of recombinant Factor VIIa in trauma. Curr. Opin. Crit. Care (2004) 10:520-528.
   PubMedGoogle Scholar
• GOODNOUGH LT, LUBLIN DM, ZHANG L et al.: Transfusion medicine service policies for recombinant Factor VIIa administration. Transfusion (2004) 44(9):1325-1331.
   PubMed Web of Science ®Google Scholar
• BARLETTA JF, AHRENS CL, TYBURSKI JG, WILSON RF: A review of recombinant Factor VII for refractory bleeding in nonhemophilic trauma patients. J. Trauma (2005) 58(3):646-651.
   PubMed Web of Science ®Google Scholar
• MARTINOWITZ U, KENET G, SEGAL E et al.: Recombinant activated Factor VII for adjunctive hemorrhage control in trauma. J. Trauma (2001) 51:431-439.
   PubMed Web of Science ®Google Scholar
• MARTINOWITZ U, KENET G, LUBETSKI A et al.: Possible role of recombinant activated Factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can. J. Anesth. (2002) 49:S15-S20.
   PubMed Web of Science ®Google Scholar
• DUTTON RP, HESS JR, SCALEA TM: Recombinant Factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J. Clin. Anesth. (2003) 15:184-188.
   PubMed Web of Science ®Google Scholar
• EIKELBOOM JW, BIRD R, BLYTHE D et al.: Recombinant activated Factor VII for the treatment of life-threatening hemorrhage. Blood Coagul. Fibrinolysis (2003) 14:713-717.
   PubMed Web of Science ®Google Scholar
• BOFFARD KD, RIOU B, WARREN B et al.: Recombinant Factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo controlled, double-blind clinical trials. J. Trauma (2005) 59:8-18.
   PubMed Web of Science ®Google Scholar
• RIOU B, BOFFARD K, WARREN B et al.: Recombinant Factor VIIa (NovoSeven) as adjunctive therapy for bleeding control in trauma – a randomized, placebo-controlled trial. Shock (2004) 21(2):76.
   Google Scholar
• ROSSAINT R, BOFFARD KD, WARREN BL et al.: Decreased transfusion utilization using recombinant Factor VIIa as an adjunct in trauma. Crit. Care Med. (2004) 30(1):S199. Abstract 771.
   Google Scholar
• ROSSAINT R, RIOU B, BOFFARD K et al.: A randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of rFVIIa as adjunctive therapy for control of bleeding in patients with severe blunt trauma – a re-analysis following exclusion of early (< 48 hours) deaths. Critical Care (2005) 9(1):S142. Abstract P337.
   Google Scholar